Evidence map›Paper›PMID 24508552›Full record

ArticleInternational journal of pharmaceutics2014

Development of high efficiency ventilation bag actuated dry powder inhalers.

Srinivas R B Behara, P Worth Longest, Dale R Farkas, Michael Hindle

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Administration of dry powders during respiratory supports.Annals of translational medicine · 2021
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.Journal of aerosol medicine and pulmonary drug delivery · 2018
    Article
  13. Article
  14. Article
  15. Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.Journal of aerosol medicine and pulmonary drug delivery · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Srinivas R B BeharaDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States; Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, United States.
P Worth LongestDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States; Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, United States. Electronic address: pwlongest@vcu.edu.
Dale R FarkasDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States.
Michael HindleDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, United States.

Funding

High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept StudyR01HL107333 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HINDLE, MICHAEL, LONGEST, P. WORTH · 2011 to 2020
$4.2M
NHLBI NIH HHS R01 HL107333
6 · The paper itself

Abstract

New active dry powder inhaler systems were developed and tested to efficiently aerosolize a carrier-free formulation. To assess inhaler performance, a challenging case study of aerosol lung delivery during high-flow nasal cannula (HFNC) therapy was selected. The active delivery system consisted of a ventilation bag for actuating the device, the DPI containing a flow control orifice and 3D rod array, and streamlined nasal cannula with separate inlets for the aerosol and HFNC therapy gas. In vitro experiments were conducted to assess deposition in the device, emitted dose (ED) from the nasal cannula, and powder deaggregation. The best performing systems achieved EDs of 70-80% with fine particle fractions <5 μm of 65-85% and mass median aerodynamic diameters of 1.5 μm, which were target conditions for controlled condensational growth aerosol delivery. Decreasing the size of the flow control orifice from 3.6 to 2.3mm reduced the flow rate through the system with manual bag actuations from an average of 35 to 15LPM, while improving ED and aerosolization performance. The new devices can be applied to improve aerosol delivery during mechanical ventilation, nose-to-lung aerosol administration, and to assist patients that cannot reproducibly use passive DPIs.

Indexed as

Dry Powder InhalersAdministration, InhalationAerosolsAlbuterolChemistry, PharmaceuticalDrug Delivery SystemsEquipment DesignHumansParticle SizeRespiration, ArtificialTechnology, PharmaceuticalAerosolsAlbuterolActive dry power inhaler (DPI)Excipient enhanced growth (EEG) formulationHigh efficiency DPINoninvasive ventilationNose to lung aerosol deliveryStreamlined ventilation components

Identifiers

PMID24508552
PMCPMC4051231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.